The phrase "alternative efficacy" is correct and usable in written English.
It can be used in contexts discussing the effectiveness of different methods, treatments, or approaches, particularly in fields like medicine or research.
Example: "The study aimed to compare the alternative efficacy of two different therapies for treating chronic pain."
Alternatives: "alternative effectiveness" or "substitute efficacy".
Sensitivity analyses were conducted using alternative efficacy and tolerability data.
While this is statistically significant, the percentage fails to meet the FDA's alternative efficacy criteria of 5% placebo-adjusted weight loss, according to one media source.
Improvements in clinical symptoms were also evident when assessing remission as an alternative efficacy parameter.
The primary efficacy endpoint was the proportion of patients achieving a Hgb increase of ≥2.0 g/dL at any time from Baseline to Week 5. To meet the requests of different health authorities, an additional alternative efficacy analysis was conducted.
We conducted a simulation study with consideration of the pathological characteristics of MS, and applied alternative efficacy estimation methods to real clinical trial data, including 5 extended Cox regression models for time-to-event analysis, a Poisson regression model and a Poisson regression model with Generalized Estimating Equations (GEE).
Ferumoxytol was superior to placebo, with a clinically meaningful and statistically significantly greater increase in mean Hgb levels in the ferumoxytol group from Baseline to Week 5 (2.7 g/dL) compared with the placebo group (0.1 g/dL; treatment difference: 2.54 g/dL; P < 0.0001); this was also the predefined primary efficacy endpoint in the pre-defined alternative efficacy analysis.
Since the beginning of the growth period, the notion of TKM research was expanded as a substitute for Western medicine through the discovery of alternative efficacies, mechanisms of new action, and novel substances as part of a large-scale project.
We conducted analyses using alternative vaccine efficacy data by following the WHO SAGE recommendation for efficacy data extrapolation across countries.
Health related quality of life (HRQOL) indicators take into account the personal perception of health, and are proposed as an alternative for efficacy indicators in medical and therapeutic decision-making.
This endpoint has been recently validated by a study which showed that six-month progression-free survival can be used as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide [27].
As an alternative, the efficacy of chemotherapy in the treatment of brain metastases has been investigated.
